| Name | Title | Contact Details |
|---|
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
Fastrack Pharmaceuticals is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lexigen is a Nashua, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Hoechst AG is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.